Literature DB >> 20231923

SV2A in epilepsy: the plot thickens.

Graeme J Sills.   

Abstract

Entities:  

Year:  2010        PMID： 20231923      PMCID： PMC2836477          DOI： 10.1111/j.1535-7511.2009.01351.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  11 in total

1.  SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release.

Authors:  R Janz; Y Goda; M Geppert; M Missler; T C Südhof
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

2.  SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family.

Authors:  R Janz; T C Südhof
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

3.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).

Authors:  K M Crowder; J M Gunther; T A Jones; B D Hale; H Z Zhang; M R Peterson; R H Scheller; C Chavkin; S M Bajjalieh
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy.

Authors:  Jan A Gorter; Erwin A van Vliet; Eleonora Aronica; Timo Breit; Han Rauwerda; Fernando H Lopes da Silva; Wytse J Wadman
Journal:  J Neurosci       Date:  2006-10-25       Impact factor: 6.167

Review 5.  Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsia       Date:  2006-08       Impact factor: 5.864

6.  Levetiracetam in refractory epilepsy: a prospective observational study.

Authors:  Rajiv Mohanraj; Pamela G Parker; Linda J Stephen; Martin J Brodie
Journal:  Seizure       Date:  2005-01       Impact factor: 3.184

7.  SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.

Authors:  Rafal M Kaminski; Alain Matagne; Karine Leclercq; Michel Gillard; Philippe Michel; Benoit Kenda; Patrice Talaga; Henrik Klitgaard
Journal:  Neuropharmacology       Date:  2007-12-08       Impact factor: 5.250

8.  Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.

Authors:  Rafal M Kaminski; Michel Gillard; Karine Leclercq; Etienne Hanon; Geneviève Lorent; Donald Dassesse; Alain Matagne; Henrik Klitgaard
Journal:  Epilepsia       Date:  2009-04-19       Impact factor: 5.864

9.  Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.

Authors:  Erwin A van Vliet; Eleonora Aronica; Sandra Redeker; Karin Boer; Jan A Gorter
Journal:  Epilepsia       Date:  2008-08-19       Impact factor: 5.864

10.  Development of tolerance to levetiracetam in rats with chronic epilepsy.

Authors:  Erwin A van Vliet; Rosalinda van Schaik; Peter M Edelbroek; Fernando H Lopes da Silva; Wytse J Wadman; Jan A Gorter
Journal:  Epilepsia       Date:  2008-07       Impact factor: 5.864
View more
  5 in total

1.  Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.

Authors:  Jing Shi; Feng Zhou; Li-Kun Wang; Guo-Feng Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.

Authors:  Yifan Zhang; Lise Heylen; Michèle Partoens; James D Mills; Rafal M Kaminski; Patrice Godard; Michel Gillard; Peter A M de Witte; Aleksandra Siekierska
Journal:  Front Mol Neurosci       Date:  2022-05-24       Impact factor: 6.261

3.  Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.

Authors:  Marine Douaud; Katia Feve; Fabienne Pituello; David Gourichon; Simon Boitard; Eric Leguern; Gérard Coquerelle; Agathe Vieaud; Cesira Batini; Robert Naquet; Alain Vignal; Michèle Tixier-Boichard; Frédérique Pitel
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

Review 4.  Imaging Synaptic Density: The Next Holy Grail of Neuroscience?

Authors:  Maria Elisa Serrano; Eugene Kim; Marija M Petrinovic; Federico Turkheimer; Diana Cash
Journal:  Front Neurosci       Date:  2022-03-25       Impact factor: 4.677

5.  Chronic levetiracetam (Keppra®) treatment increases the reinforcing strength of cocaine in rhesus monkeys.

Authors:  Paul W Czoty; Robert W Gould; Cormac A O'Donovan; Michael A Nader
Journal:  Pharmacol Biochem Behav       Date:  2021-06-08       Impact factor: 3.697
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.